Archives of Medical Research
Volume 40, Issue 7 , Pages 536-544 , October 2009

Effect of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor (Vildagliptin) on Peripheral Nerves in Streptozotocin-induced Diabetic Rats

  • Heung Yong Jin
    • ,
  • Wei Jing Liu
    • ,
  • Ji Hyun Park
    • ,
  • Hong Sun Baek
    • ,
  • Tae Sun Park

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Tae Sun Park, M.D., Ph.D., Division of Endocrinology and Metabolism, Department of Internal Medicine, Chonbuk National University Medical School, 634-18, Keum-Am Dong, Jeonju, 561-712, South Korea; Phone: 82-63-250-1794; FAX: 82-63-254-1609

Received 26 June 2009 ,Accepted 7 September 2009.

References 

  1. Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006;81(suppl 4):S3–S11
  2. Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am. 2004;88:947–999xi
  3. Sima AA, Thomas PK, Ishii D, et al. Diabetic neuropathies. Diabetologia. 1997;40(suppl 3):B74–B77
  4. Boulton AJ, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458–1486
  5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853
  6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854–865
  7. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006;81(suppl 4):S12–S25
  8. Siemionow M, Demir Y. Diabetic neuropathy: pathogenesis and treatment. J Reconstr Microsurg. 2004;20:241–252
  9. Estall JL, Drucker DJ. Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des. 2006;12:1731–1750
  10. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept. 2005;128:135–148
  11. Perry T, Lahiri DK, Chen D, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002;300:958–966
  12. Perry T, Holloway HW, Weerasuriya A, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol. 2007;203:293–301
  13. Biswas SC, Buteau J, Greene LA. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem Res. 2008;33:1845–1851
  14. Nakagawa A, Satake H, Nakabayashi H, et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci. 2004;110:36–43
  15. Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol. 2004;4:589–596
  16. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929–2940
  17. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998;47:1663–1670
  18. Burkey BF, Li X, Bolognese L, et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther. 2005;315:688–695
  19. Kiso T, Nagakura Y, Toya T, et al. Neurometer measurement of current stimulus threshold in rats. J Pharmacol Exp Ther. 2001;297:352–356
  20. Beiswenger KK, Calcutt NA, Mizisin AP. Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem. 2008;110:351–362
  21. Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med. 1999;107:34S–42S
  22. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9:1173–1179
  23. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20:876–913
  24. Perry T, Greig NH. The glucagon-like peptides: a double-edged therapeutic sword?. Trends Pharmacol Sci. 2003;24:377–383
  25. Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol. 2007;18:1227–1238
  26. Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694–699
  27. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia. 2006;49:253–260
  28. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888–4894
  29. Fricker B, Muller A, Rene F. Evaluation tools and animal models of peripheral neuropathies. Neurodegener Dis. 2008;5:72–108
  30. Buteau J. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab. 2008;34(Suppl 2):S73–S77

 Conflict of interest: None

PII: S0188-4409(09)00182-9

doi: 10.1016/j.arcmed.2009.09.005

Archives of Medical Research
Volume 40, Issue 7 , Pages 536-544 , October 2009

Article Tools

* Image Usage & Resolution